D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$862M |
| 2 |
Baidu
BIDU
|
+$752M |
| 3 |
Tencent Music
TME
|
+$426M |
| 4 |
Coca-Cola
KO
|
+$424M |
| 5 |
NVIDIA
NVDA
|
+$383M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$981M |
| 2 |
Wells Fargo
WFC
|
+$673M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$574M |
| 4 |
Moderna
MRNA
|
+$442M |
| 5 |
DuPont de Nemours
DD
|
+$415M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.93% |
| 2 | Consumer Discretionary | 10.48% |
| 3 | Healthcare | 8.56% |
| 4 | Communication Services | 8.41% |
| 5 | Financials | 6.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
PUT
Viatris
VTRS
$20.8B
| $3M | ﹤0.01% |
214,876
-547,620
| -72% | -$8.92M |
|
|
NXGN
2102
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $3M | ﹤0.01% |
165,880
-117,459
| -41% | -$2.32M |
|
|
GTH
2103
DELISTED
Genetron Holdings Limited ADS
GTH
| $3M | ﹤0.01% |
46,564
+6,114
| +15% | +$420K |
|
|
EXK
2104
Endeavour Silver
EXK
$2.29B
| $3M | ﹤0.01% |
+604,324
| New | +$3.24M |
|
2105
CALL
Abbott
ABT
$187B
| $3M | ﹤0.01% |
25,000
-75,000
| -75% | -$8.89M |
|
2106
Marathon Petroleum
MPC
$89.3B
| $2.99M | ﹤0.01% |
55,896
+41,372
| +285% | +$2.09M |
|
2107
CALL
Ubiquiti
UI
$32.4B
| $2.98M | ﹤0.01% |
10,000
-74,700
| -88% | -$23.5M |
|
2108
OFG Bancorp
OFG
$2.24B
| $2.98M | ﹤0.01% |
131,819
-6,864
| -5% | -$136K |
|
|
PDOT.U
2109
DELISTED
Peridot Acquisition Corp. II Units, each consisting of one Class A ordinary share, and one-fifth of one redeemable warrant
PDOT.U
| $2.98M | ﹤0.01% |
+300,000
| New | +$2.98M |
|
2110
E.W. Scripps
SSP
$282M
| $2.97M | ﹤0.01% |
153,949
+23,955
| +18% | +$441K |
|
2111
J.M. Smucker
SJM
$13.2B
| $2.96M | ﹤0.01% |
23,437
-74,635
| -76% | -$8.81M |
|
2112
CALL
Sabre
SABR
$743M
| $2.96M | ﹤0.01% |
+200,000
| New | +$2.71M |
|
|
FTEV.U
2113
DELISTED
FinTech Evolution Acquisition Group Units, each consisting of one Class A Ordinary Share, and one-third of one redeemable warrant
FTEV.U
| $2.96M | ﹤0.01% |
+300,000
| New | +$3M |
|
2114
PUT
CoStar Group
CSGP
$12.4B
| $2.96M | ﹤0.01% |
+36,000
| New | +$3.11M |
|
|
SCS
2115
DELISTED
Steelcase
SCS
| $2.95M | ﹤0.01% |
205,020
-188,852
| -48% | -$2.68M |
|
2116
Vera Bradley
VRA
$104M
| $2.95M | ﹤0.01% |
291,901
-96,928
| -25% | -$912K |
|
2117
CALL
American Express
AXP
$227B
| $2.94M | ﹤0.01% |
20,800
-100,100
| -83% | -$13.2M |
|
2118
SiTime
SITM
$14.7B
| $2.94M | ﹤0.01% |
29,831
+3,801
| +15% | +$445K |
|
|
FVT
2119
DELISTED
Fortress Value Acquisition Corp. III
FVT
| $2.94M | ﹤0.01% |
+297,078
| New | +$2.97M |
|
2120
PetMed Express
PETS
$43M
| $2.94M | ﹤0.01% |
83,418
+76,510
| +1,108% | +$2.66M |
|
2121
Sixth Street Specialty
TSLX
$1.68B
| $2.93M | ﹤0.01% |
139,379
+62,838
| +82% | +$1.35M |
|
2122
Arrowhead Research
ARWR
$12.1B
| $2.93M | ﹤0.01% |
44,185
-44,414
| -50% | -$3.45M |
|
2123
PUT
QuidelOrtho
QDEL
$1.14B
| $2.93M | ﹤0.01% |
+22,900
| New | +$4.23M |
|
2124
PUT
Macerich
MAC
$7.52B
| $2.93M | ﹤0.01% |
+250,300
| New | +$3.35M |
|
2125
CryoPort
CYRX
$765M
| $2.93M | ﹤0.01% |
56,261
-270,710
| -83% | -$16.5M |
|
Similar funds
D.E. Shaw & Co's Q1 2021 Portfolio in Review
As of Q1 2021, D.E. Shaw & Co held 4,712 positions worth $104B, down 7.4% from $112B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
D.E. Shaw & Co withdrew a net $18.3B in Q1 2021, closing 730 positions and reducing 1,773 holdings. Its most notable exit was AstraZeneca, an estimated $214M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, D.E. Shaw & Co opened a new position in Baidu worth $627M.
- D.E. Shaw & Co's largest Q1 2021 buy was Baidu: 2,881,724 shares worth $627M.
- D.E. Shaw & Co added most to Tesla in Q1 2021, an estimated $862M increase.
- D.E. Shaw & Co's biggest Q1 2021 reduction was Amazon, cutting an estimated $981M.
- D.E. Shaw & Co fully exited AstraZeneca in Q1 2021, selling an estimated $214M.
- D.E. Shaw & Co's ten largest holdings make up 9.9% of its $104B portfolio in Q1 2021.
- D.E. Shaw & Co opened 825 new positions and closed 730 in Q1 2021.
- D.E. Shaw & Co's portfolio value fell 7.4% quarter-over-quarter to $104B.
Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.